GHK-Cu: Evidence, Safety, Dosing, and How It’s Used

GHK-Cu is a copper-binding tripeptide, also called copper peptide or glycyl-L-histidyl-L-lysine copper, studied mainly for topical skin remodeling and wound-related uses. Human evidence is limited: Chia grades it B because one randomized human trial is indexed in PubMed. It should be considered through clinician review, not self-directed use.

What it is

GHK-Cu is a copper-binding tripeptide: glycine, histidine, and lysine joined together and complexed with copper. In the literature, it may be called copper peptide, copper tripeptide complex, glycyl-L-histidyl-L-lysine copper, or glycyl-L-histidyl-L-lysine-Cu(2+) 1, 2.

Names: GHK-Cu, copper peptide, and glycyl-L-histidyl-L-lysine copper

There is no separate brand-name GHK-Cu product listed in Chia’s offerings. The practical patient-facing term is usually “GHK-Cu cream” or “copper peptide cream,” while scientific papers often use the longer chemical name 2, 4.

Why people look for GHK-Cu

Most patient interest is in skin quality, texture, visible aging, and wound-related research. Reviews describe topically applied GHK as an anti-wrinkle peptide area with possible advantages, delivery problems, and research gaps, so the honest framing is “studied for skin applications,” not “proven to reverse aging” 4.

Mechanism of action

GHK-Cu’s mechanism is best understood as proposed and model-based, not fully proven in humans. Reviews describe possible regenerative and protective actions, including gene-expression pathways, but those data do not prove broad clinical outcomes for patients 2.

Copper-binding tripeptide basics

GHK-Cu binds copper, and copper is involved in normal biology, including enzymes tied to connective tissue and oxidative stress pathways. That biology helps explain why GHK-Cu is studied in skin and repair models, but mechanism is not the same as a proven patient benefit 2, 4.

Skin remodeling and repair pathways studied in the literature

Skin-focused reviews describe topical GHK research around wrinkles, delivery into the skin, formulation limits, and tissue-remodeling hypotheses. A 2023 study also explored GHK-Cu with hyaluronic acid in fibroblast and ex-vivo skin tests, which is laboratory and tissue-model evidence rather than a clinical outcome study in patients 4, 12.

Why preclinical mechanisms should not be treated as proven human outcomes

Animal and cell studies can show what researchers think may be happening, but they do not prove that a person will see the same result. For example, studies have examined GHK-Cu in animal or model systems related to skeletal muscle dysfunction, inflammation, and oxidative stress; those findings should stay in the “early research” category 7, 10, 11.

Evidence

Evidence grade: B. Chia uses this grade because the supplied PubMed set includes 1 randomized human trial of a topical copper tripeptide complex, plus reviews and preclinical studies. Grade B does not mean GHK-Cu is proven to work or safe for every person 1.

What a Grade B rating means for patients

A Grade B rating means there is some human trial evidence, but the evidence base is still small. It is stronger than animal-only evidence, but it is not enough to support broad claims about longevity, lifespan, whole-body repair, athletic performance, or disease outcomes 1, 4, 9.

What the human randomized trial can and cannot show

The key human trial in this record set studied a topical copper tripeptide complex on CO2 laser-resurfaced skin. That makes it relevant to topical skin recovery after a procedure, but it does not prove that GHK-Cu injections, general skin-care use, or systemic anti-aging use will produce the same results 1.

What reviews and preclinical studies add

Reviews add useful context about proposed mechanisms, delivery challenges, and why topical GHK-Cu remains an active research topic. Primary preclinical studies add signals in models, such as skeletal muscle dysfunction in a cigarette-smoke model and inflammation in zebrafish larvae, but those are not human clinical outcomes 2, 4, 7, 10.

Evidence limits: no proven human longevity or lifespan claim

A study titled “The potential of GHK as an anti-aging peptide” exists in the supplied record set, and that title reflects active research interest. It should not be read as proof that GHK-Cu extends human lifespan or produces a proven longevity outcome in people 3.

What studies exist

This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-02.

Reported dosing ranges

GHK-Cu dosing should not be self-directed. The retrieved records do not provide a patient-ready dosing range for this article to repeat, and this page should not be used to decide how much to apply or inject 1, 4.

Why this article should not give personal dosing instructions

Dosing depends on the form, skin condition, medical history, other products used, and clinician judgment. Injection use raises different evidence and safety questions than topical use, and sports-medicine reviews warn that peptide use often involves uncertainty around safety, supply quality, and clinical evidence 6, 9.

Topical products versus injections: different risk and evidence questions

Topical GHK-Cu is applied to the skin and is the form most connected to the human and skin-focused literature in this evidence set. Injectable peptide therapy is discussed in sports-medicine reviews as a separate area with safety, sourcing, and evidence concerns, so it should not be treated as interchangeable with topical use 1, 4, 6.

What patients should ask a clinician before using GHK-Cu

• Is topical GHK-Cu appropriate for my skin history and goals?
• Should I avoid it around a recent procedure, open wound, rash, or infection?
• Could my current skin-care actives make irritation more likely?
• How should I monitor for redness, burning, itching, or worsening irritation?
• What should I do if I become pregnant, start breastfeeding, or develop a new medical condition?

Legal status

Our regulatory log holds no confirmed federal action for GHK-Cu. That means we have not found one with a primary source — not that none exists.

This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-02. See the full legal-status tracker for every compound we follow.

Safety

GHK-Cu safety is not fully defined across all forms and uses. The main human evidence in this record set is topical and limited, while reviews of peptide therapies note broader concerns about unapproved peptide use, injectable products, and supply quality 1, 6, 9.

Local skin reactions and tolerability questions

For topical use, the practical safety questions include redness, burning, stinging, itching, dryness, or irritation, especially if the skin barrier is already disrupted. The supplied human trial involved CO2 laser-resurfaced skin, so procedure-related irritation is an important context rather than a detail to ignore 1.

Unknowns with non-topical use

Non-topical use should be treated as a different question. Reviews on injectable peptide therapy and peptide use in sports medicine discuss the need for caution around efficacy, safety, and oversight, but they do not establish GHK-Cu injection benefits or a reassuring safety profile for patients 5, 6, 9.

Why purity, compounding quality, and clinician oversight matter

Products sold as “research use only” are not medical care and are not made for a clinician to monitor in a patient. The key risks are identity, sterility, strength, impurities, and no medical review before use; sports-medicine reviews describe these supply and oversight concerns across peptide therapy 6, 9, 11.

Who should be cautious with GHK-Cu

People who are pregnant, breastfeeding, have active skin disease, have an open wound, have a skin infection, or recently had a cosmetic procedure should get clinician guidance before using topical GHK-Cu. The reason is simple: the human evidence base is narrow, and irritated or healing skin may react differently than intact skin 1, 4.

Interactions

No dedicated GHK-Cu interaction studies are available in the supplied evidence set. That is not the same as proof of no interactions; it means medication, supplement, skin-care, allergy, and procedure history should be reviewed by a clinician 4, 9.

Skin-care actives and procedure-related irritation

The most practical interaction question is skin irritation. Retinoids, exfoliating acids, benzoyl peroxide, recent peels, laser procedures, microneedling, rashes, and barrier damage may change tolerability, and the key human trial’s procedure context makes that point clinically relevant 1, 4.

Supplements, medications, and medical history review

Because the supplied records do not provide clear drug-interaction data, a medical review should include prescription medicines, supplements, topical products, allergies, pregnancy status, wound history, and skin conditions. This is especially important when a peptide is being considered outside the best-studied topical context 6, 9.

How to obtain it legally

The medical process starts with a health history, medication review, skin and goal review, and a licensed clinician deciding whether treatment is appropriate. At Chia, we offer GHK-Cu cream only; plans currently start at $159/month, and a prescription requires a medical evaluation and is not guaranteed.

GHK-Cu at Chia: topical cream with clinician review

Chia’s GHK-Cu option is a compounded topical cream. We do not list GHK-Cu injections, tablets, or sprays in our current offerings, so our clinical pathway is focused on topical use and provider-guided care.

How Chia’s online evaluation works

1. 1Start with the eligibility quiz or a short online health questionnaire.
2. 2A licensed US provider reviews your goals, medical history, medications, and safety factors.
3. 3If treatment is clinically appropriate, the provider writes a prescription and guides use over time.
4. 4Medication is compounded by a state-licensed US 503A pharmacy and shipped to your door.
5. 5You can message your care team through the patient portal between visits.

Compounded drugs are not FDA-approved. That means they are not reviewed by FDA for safety, effectiveness, or quality before dispensing, so the licensed-provider and state-licensed-pharmacy process matters.

Where GHK-Cu may fit alongside the Glow protocol

Chia also lists the Glow protocol, which includes GHK-Cu cream with glutathione injection and NAD+ injection. That does not mean the combination has been proven to produce a specific outcome; it means a clinician can review whether the protocol fits a patient’s goals and health history.

Why research-chemical vendors are not medical care

A research-chemical seller does not replace a medical evaluation, prescription decision, pharmacy quality process, or follow-up care. Reviews of peptide therapy highlight safety and efficacy concerns in settings where products and use are not medically supervised 6, 9.

DoctorMCP note

When appropriate, Chia can also be reachable by AI agents through DoctorMCP at mcp.chia.health. The clinical step does not change: a licensed provider must still review eligibility, and treatment is never guaranteed.

Keep reading

Peptides

GHK-Cu Peptide Injection Dosage: Protocols, Cycles, and Safety

Peptides

Peptides for Inflammation: What the Evidence Says and What to Ask a Clinician

Longevity

Peptides for Hair Growth: What the Evidence Says